RNS Number : 8114S
Tudor Capital Europe LLP
12 February 2026
Ap27
FORM 8.3
IRISH TAKEOVER PANEL
OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
1. KEY INFORMATION
(a) Full name of discloser
Tudor Investment Corporation
(b) Owner or controller of interests and shortpositions disclosed, if different from 1(a) The naming of nominee or vehicle companies isinsufficient. For a trust, the trustee(s), settlor andbeneficiaries must be named.
N/A
(c) Name of offeror/offeree in relation to whoserelevant securities this form relates Use a separate form for each offeror/offeree
Avadel Pharmaceuticals Plc
(d) If an exempt fund manager connected with anofferor/offeree, state this and specify identityof offeror/offeree(Note 1)
N/A
(e) Date position held/dealing undertaken For an opening position disclosure, state thelatest practicable date prior to the disclosure
11/02/2026
(f) In addition to the company in 1(c) above, is thediscloser also making disclosures in respectof any other party to the offer? If it is a cash offer or possible cash offer, state"N/A"
No
2. INTERESTS AND SHORT POSITIONS
If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.
Ap28
Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
(Note 2)
Class of relevant security(Note 3)
$0.01 ordinary shares
Interests
Short positions
Number
%
Number
%
(1) Relevant securities owned and/or controlled
3,184,654
3.2446
198,792
0.2025
(2) Cash-settled derivatives
2,798
0.0029
(3) Stock-settled derivatives(including options) andagreements to purchase/sell
1,100
0.0011
2,200
0.0022
Total
3,185,754
3.2457
203,790
0.2076
All interests and all short positions should be disclosed.
Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
The currency of all prices and other monetary amounts should be stated.
(a) Purchases and sales
Class of relevant security
Purchase/sale
Number of securities
Price per unit(Note 5)
Ordinary
Purchase
982
21.63
Ordinary
Sale
10
21.66
Ordinary
Sale
1
21.67
Ordinary
Sale
7
21.68
Ordinary
Sale
20
21.69
Ordinary
Sale
5
21.7
Ordinary
Sale
5
21.71
Ordinary
Sale
5
21.74
Ordinary
Sale
1
21.75
Ap29
(b) Cash-settled derivative transactions
Class ofrelevantsecurity
Productdescriptione.g. CFD
Nature of dealinge.g. opening/closing a long/short position,increasing/ reducing a long/ short position
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Class ofrelevantsecurity
Nature of dealinge.g. subscription,conversion, exercise
Details
Price per unit (ifapplicable)(Note 5)
N/A
Ap30
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreementor understanding, formal or informal, relating to relevant securitieswhich may be an inducement to deal or refrain from dealingentered into by the person making the disclosure and any party tothe offer or any person acting in concert with a party to the offer. Irrevocable commitments and letters of intent should not be included. Ifthere are no such agreements, arrangements or understandings, state"none"
None
(b) Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understandingbetween the person disclosing and any other person relatingto the voting rights of any relevant securities under any optionreferred to on this form or relating to the voting rights or futureacquisition or disposal of any relevant securities to which anyderivative referred to on this form is referenced. If none, thisshould be stated.
None
(c) Attachments
Is a Supplemental Form 8 attached?
YES/NO
Date of disclosure
12/02/2026
Contact name
Ben Kitchener
Telephone number
+44 (203) 755-3935
Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.
Ap31
NOTES ON FORM 8.3
1. See the definition of "connected fund manager" in Rule 2.2 of Part A of the Rules.
2. See the definition of "interest in a relevant security" in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.
3. See the definition of "relevant securities" in Rule 2.1 of Part A of the Rules.
4. See the definition of "dealing" in Rule 2.1 of Part A of the Rules.
5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.
6. See Rule 2.5(d) of Part A of the Rules.
7. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.
Ap32
SUPPLEMENTAL FORM 8
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND
RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2022
DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING
OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND
RIGHTS TO SUBSCRIBE FOR NEW SECURITIES
1. KEY INFORMATION
Full name of person makingdisclosure:
Tudor Investment Corporation
Name of offeror/offeree in relationto whose relevant securities thedisclosure relates:
Avadel Pharmaceuticals Plc
2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
Class ofrelevantsecurity
Productdescriptione.g. calloption
Written orpurchased
Number ofsecurities to which option or derivativerelates
Exercisepriceper unit
Typee.g.American,Europeanetc.
Expirydate
Equity Option
Put Option
Purchased
1,700
12.5
American
20.03.2026
Equity Option
Call Option
Purchased
200
15
American
20.03.2026
Equity Option
Put Option
Purchased
400
15
American
20.03.2026
Equity Option
Call Option
Purchased
800
17.5
American
20.03.2026
Equity Option
Put Option
Purchased
100
17.5
American
20.03.2026
Equity Option
Call Option
Purchased
100
20
American
20.03.2026
3. AGREEMENTS TO PURCHASE OR SELL
Full details should be given so that the nature of the interest orposition can be fully understood:
N/A
Ap33
4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS' AND OTHER EMPLOYEE OPTIONS)
Class of relevant security inrelation to which subscriptionright exists:
N/A
Details, including nature of therights concerned and relevantpercentages:
N/A
It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.
The currency of all prices and other monetary amounts should be stated.
For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.
References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ITPFLFLFFLIFLIR
